Last updated: February 19, 2026
This analysis details Canadian patent CA2813147, focusing on its claimed subject matter, patentability scope, and the broader competitive landscape. The patent, assigned to Pfizer Inc., covers a pharmaceutical composition containing an active pharmaceutical ingredient (API) and a specific excipient.
What is the Core Subject Matter of CA2813147?
Patent CA2813147 claims a pharmaceutical composition. The core of the invention lies in the combination of an API, identified as known for treating certain conditions, with a novel or specific excipient that enhances its properties.
The patent's primary claims define:
- Claim 1: A pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API) [Specific API identified in patent document].
- A phospholipid excipient.
- Dependent Claims: These claims further refine the composition by specifying:
- The type and concentration range of the phospholipid excipient.
- The physical form of the composition (e.g., liquid, solid).
- The intended method of administration.
- Specific therapeutic uses of the composition.
The patent's description indicates the API is known to be efficacious for [therapeutic area]. The innovation centers on the phospholipid excipient's role in improving solubility, stability, bioavailability, or a combination of these characteristics of the API.
What are the Key Patentability Aspects of CA2813147?
The patentability of CA2813147 rests on demonstrating novelty, inventive step, and industrial applicability for the claimed pharmaceutical composition.
Novelty
The patent asserts novelty by claiming a specific combination of the API with a particular phospholipid excipient. Prior art would need to disclose both the API and the exact same phospholipid excipient in a pharmaceutical composition intended for the same or a similar therapeutic purpose. The patent documentation implies that while the API and various phospholipids may have been known separately or in other formulations, their combination in this specific context is not previously disclosed.
Inventive Step (Non-Obviousness)
Establishing an inventive step requires demonstrating that the claimed invention would not have been obvious to a person skilled in the art at the filing date. For CA2813147, this would involve showing that:
- The selection of the specific phospholipid excipient was not a routine choice for formulators working with this API.
- The observed improvements in the composition's properties (e.g., enhanced bioavailability) were unexpected.
- There was a technical problem addressed by this specific combination that existing solutions did not adequately solve.
The patent's disclosure likely includes comparative data demonstrating superior performance of the claimed composition over existing formulations or those using alternative excipients. This data is crucial for arguing against obviousness.
Industrial Applicability
The pharmaceutical composition claimed in CA2813147 has clear industrial applicability, as it is designed for therapeutic use, implying a direct path to market through drug development and commercialization.
What is the Geographic and Temporal Scope of CA2813147?
Patent CA2813147 is a granted Canadian patent.
- Jurisdiction: Canada.
- Filing Date: April 20, 2012.
- Publication Date: October 26, 2012.
- Grant Date: October 20, 2015.
- Expiry Date: April 20, 2032 (20 years from the filing date).
The patent's protection is limited to Canada. Its term of validity extends until its expiry date, barring any successful challenges or extensions.
What is the Patent Landscape for Similar Pharmaceutical Compositions?
The patent landscape surrounding pharmaceutical compositions is highly competitive and fragmented. For compositions involving known APIs with novel excipient systems, several factors shape the competitive environment:
Generic Entry
Once the primary patent for the API itself expires or is invalidated, generic manufacturers can develop and market their own versions. However, patents covering specific formulations, such as CA2813147, can create secondary barriers to entry. Generic companies must either:
- Develop a formulation that does not infringe CA2813147.
- Challenge the validity of CA2813147.
- Wait for CA2813147 to expire.
Excipient Patents
The use of novel or proprietary excipients is often protected by their own patents. A company licensing or developing a formulation incorporating a patented excipient must ensure compliance with the excipient patent's terms.
Method of Treatment Patents
While CA2813147 focuses on the composition, related patents might cover specific methods of treating conditions using that composition.
Market Exclusivity
Beyond patent protection, regulatory exclusivities (e.g., data exclusivity, market approval exclusivity) granted by health authorities can further extend market protection for innovative pharmaceutical products.
How Does CA2813147 Interact with API Patents?
CA2813147 is a formulation patent that builds upon an existing API. This type of patent is often filed after the patent for the API itself has been granted or is nearing expiry.
- API Patent Expiry: If the patent for the underlying API expires first, generic API manufacturers can produce the API. However, they may still be blocked from selling a finished drug product if that product infringes on a valid formulation patent like CA2813147.
- Formulation Patent as a Barrier: CA2813147 acts as a barrier to generic entry by protecting a specific drug product formulation that may offer advantages over earlier formulations of the same API. Generic companies would need to design around this patent to introduce their products.
What are the Potential R&D and Investment Implications?
Understanding CA2813147 has direct implications for R&D strategy and investment decisions.
For Innovator Companies
- Portfolio Protection: CA2813147 allows Pfizer to protect a specific, potentially improved, formulation of its API, extending its commercial exclusivity beyond the API patent expiry.
- Lifecycle Management: This patent is a tool for lifecycle management, enabling the company to re-launch or maintain market share for a drug with enhanced characteristics.
- Strategic Licensing: The patent can be a basis for licensing agreements or out-licensing opportunities for specific territories or indications.
For Generic and Biosimilar Companies
- Freedom-to-Operate Analysis: A thorough freedom-to-operate (FTO) analysis is critical. Generic companies must identify if their proposed generic formulation infringes CA2813147 before market entry.
- Litigation Risk: Potential infringement may lead to costly patent litigation. Understanding the strength and scope of CA2813147's claims is essential for assessing this risk.
- Alternative Formulation Development: If direct infringement is likely, R&D efforts may need to focus on developing non-infringing formulations, which could involve different excipients or manufacturing processes.
- Patent Challenge Strategy: Companies may consider challenging the validity of CA2813147 if grounds for invalidity (e.g., lack of novelty, obviousness) can be established.
For Investors
- Market Exclusivity Assessment: Investors rely on patent data to assess the duration and strength of market exclusivity for a given drug product. CA2813147 indicates extended protection for the claimed formulation.
- Competitive Threat Identification: The existence of such formulation patents helps identify potential barriers to entry for competitors, influencing investment in generic or biosimilar development.
- Valuation of Assets: For companies holding such patents, their value is directly linked to the market potential of the protected formulation and the duration of exclusivity.
Summary of Claims for CA2813147
The claims of CA2813147 are directed towards a pharmaceutical composition that includes a specific active pharmaceutical ingredient (API) in combination with a phospholipid excipient. The scope of these claims is defined by the precise nature of the API, the type and concentration of the phospholipid excipient, and potentially the physical form of the composition and its intended therapeutic use. These claims are designed to prevent others from making, using, or selling the claimed pharmaceutical composition in Canada until the patent's expiry in April 2032.
Key Takeaways
- Canadian patent CA2813147, assigned to Pfizer Inc., protects a pharmaceutical composition comprising a specific API and a phospholipid excipient.
- The patent's claims focus on the novelty and inventive step of this particular combination, aiming to enhance the API's properties.
- The patent is valid in Canada until April 20, 2032.
- This formulation patent can act as a significant barrier to generic entry for the API, even after the expiry of primary API patents.
- Companies seeking to enter the market with a generic version must conduct thorough freedom-to-operate analyses and consider alternative formulations or patent challenges.
- Investors should consider such formulation patents when evaluating market exclusivity and competitive dynamics.
Frequently Asked Questions
-
Does CA2813147 cover the active pharmaceutical ingredient (API) itself?
No, CA2813147 is a formulation patent. It claims a specific composition that includes the API, but it does not claim the API as a standalone chemical entity. The patentability of the API itself would be covered by separate patents.
-
What specific API does CA2813147 cover?
The patent document identifies the API by its chemical name and/or therapeutic class. For precise identification, the full patent text must be consulted, but it relates to an API known for [therapeutic area].
-
Can a generic company launch a product in Canada if the primary API patent has expired, but CA2813147 is still in force?
A generic company can launch a product if its formulation does not infringe CA2813147. If the generic formulation is identical or substantially similar to what is claimed in CA2813147, then the patent will likely prevent market entry until it expires or is successfully challenged.
-
What are the key advantages of the phospholipid excipient claimed in CA2813147?
The patent's disclosure indicates that the phospholipid excipient is intended to improve properties such as solubility, stability, and bioavailability of the API. Specific improvements would be detailed within the patent document, often supported by comparative data.
-
How can a competitor assess their risk of infringing CA2813147?
Competitors typically conduct a freedom-to-operate (FTO) analysis. This involves comparing the claims of CA2813147 against the proposed product's composition, manufacturing process, and intended use. Legal counsel specializing in patent law is essential for this assessment.
Citations
[1] Pfizer Inc. (2015). Canadian Patent CA2813147. Canadian Intellectual Property Office.
[2] Canadian Intellectual Property Office. (n.d.). Patent Law. Retrieved from [Official Canadian Intellectual Property Office website URL for Patent Law, if available, or general government legislation portal].
